FIELD: pharmacology.
SUBSTANCE: invention relates to a pharmaceutical composition for sleep initiating and maintaining and prophylaxis of animal and human states that are accompanied by sleep disorders of a different nature, including a combination of active agents consisting of 0.5-45 mg of doxylamine succinate and long-acting melatonin in amount of 0.1-20 mg.
EFFECT: synergistic therapeutic effect and reduced side effects.
2 cl, 1 tbl, 5 ex
Authors
Dates
2017-05-30—Published
2016-02-18—Filed